Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis
Abstract
Retroperitoneal fibrosis (RPF) refers to a fibro-inflammatory lesion in the retroperitoneum, often anterolateral to the aorta. Most cases are due to IgG4-related disease (IgG4-RD) or are idiopathic. RPF can lead to severe morbidity. Treatment strategies remain poorly-defined. We evaluated the efficacy and safety of rituximab (RTX) for idiopathic or IgG4-related RPF. We retrospectively reviewed the records of patients who had RPF treated with...
Paper Details
Title
Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis
Published Date
Oct 1, 2018
Journal
Volume
97
Issue
42
Pages
e12631 - e12631
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History